Immunic Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
26.7%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$4.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
| ENSURE-1 & ENSURE-2 Phase 3 Top-line Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly186.6MTarget: Sufficient to fund operations into late 2027
Research and Development (R&D) Expenses Quarterly25.6MTarget: Manageable clinical trial spend to preserve runway
Watch Items
- ENSURE-1 and ENSURE-2 Phase 3 Top-line Data ReadoutTrigger: Release of top-line data in Relapsing Multiple Sclerosis (RMS)Action: Evaluate clinical efficacy and safety profile to prepare for NDA submission in mid-2027
- CALLIPER Phase 2 Top-line Data ReadoutTrigger: Release of top-line data in Progressive Multiple Sclerosis (PMS)Action: Assess neuroprotective potential and plan next clinical steps for PMS program
- EMPhASIS Phase 2 Top-line Data ReadoutTrigger: Release of top-line data in Ulcerative Colitis (UC)Action: Review therapeutic activity of vidofludimus calcium in gastrointestinal indications
Research as of 19 Jun 2026